OTCMKTS:ABLYF - Ablynx Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$50.63Today's Range$50.63 - $50.6352-Week Range$12.50 - $55.04VolumeN/AAverage VolumeN/AMarket Capitalization$3.81 billionP/E RatioN/ADividend YieldN/ABeta4.24 ProfileDiscussionAnalyst RatingsChartHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium. Receive ABLYF News and Ratings via Email Sign-up to receive the latest news and ratings for ABLYF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ABLYF Previous SymbolNASDAQ:ABLYF CUSIPN/A Webwww.ablynx.com Phone329-262-0000 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$62.73 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees438 Outstanding Shares75,250,000Market Cap$3.81 billion OptionableNot Optionable Ablynx (OTCMKTS:ABLYF) Frequently Asked Questions What is Ablynx's stock symbol? Ablynx trades on the OTCMKTS under the ticker symbol "ABLYF." Has Ablynx been receiving favorable news coverage? Media stories about ABLYF stock have trended positive on Wednesday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ablynx earned a news sentiment score of 2.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. Who are some of Ablynx's key competitors? Some companies that are related to Ablynx include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), bluebird bio (BLUE), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Denali Therapeutics (DNLI) and Atara Biotherapeutics (ATRA). Who are Ablynx's key executives? Ablynx's management team includes the folowing people: Dr. Edwin Moses, Chief Exec. Officer and Director (Age 64)Mr. Wim Ottevaere, Chief Financial Officer (Age 62)Mr. Piet Houwen, Chief Operations OfficerDr. Robert Friesen Ph.D., Chief Scientific OfficerLies Vanneste, Director of Investor Relations How do I buy shares of Ablynx? Shares of ABLYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. How big of a company is Ablynx? Ablynx has a market capitalization of $3.81 billion and generates $62.73 million in revenue each year. Ablynx employs 438 workers across the globe. What is Ablynx's official website? The official website for Ablynx is http://www.ablynx.com. How can I contact Ablynx? Ablynx's mailing address is TECHNOLOGIEPARK 21 ZWIJNAARDE, GHENT C9, 9052. The company can be reached via phone at 329-262-0000. MarketBeat Community Rating for Ablynx (OTCMKTS ABLYF)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 127 (Vote Outperform)Underperform Votes: 175 (Vote Underperform)Total Votes: 302MarketBeat's community ratings are surveys of what our community members think about Ablynx and other stocks. Vote "Outperform" if you believe ABLYF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABLYF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2018 by MarketBeat.com StaffFeatured Article: What does cost of debt say about a company’s financial health?